{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:46:47Z","timestamp":1762004807899},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ymgme.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T21:15:52Z","timestamp":1463260552000},"page":"319-325","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Fabry in the older patient: Clinical consequences and possibilities for treatment"],"prefix":"10.1016","volume":"118","author":[{"given":"Olivier","family":"Lidove","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Bizjajeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2016.05.009_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1012447102358","article-title":"Natural history of Fabry disease in affected males and obligate carrier females","volume":"24","author":"MacDermot","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0035","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0040","series-title":"GeneReviews(R), Seattle (WA)","article-title":"Fabry Disease","author":"Mehta","year":"1993"},{"year":"2005","author":"Hughes","series-title":"Guidelines for the diagnosis and management of Anderson-Fabry disease","key":"10.1016\/j.ymgme.2016.05.009_bb0045"},{"key":"10.1016\/j.ymgme.2016.05.009_bb0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"JASN"},{"key":"10.1016\/j.ymgme.2016.05.009_bb0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cge.12585","article-title":"Fabry disease in a geriatric population","volume":"88","author":"Barbey","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0070","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0075","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0080","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2016.05.009_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0095","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ijcp.12016","article-title":"Multidimensional analysis of clinical symptoms in patients with Fabry's disease","volume":"67","author":"Kaminsky","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0110","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00004872-200018060-00001","article-title":"Clinical value of microalbuminuria in hypertension","volume":"18","author":"Rosa","year":"2000","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0115","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/j.1755-3768.2012.02576.x","article-title":"Computer assisted evaluation of retinal vessels tortuosity in Fabry disease","volume":"91","author":"Sodi","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ymgme.2016.05.009_bb0120","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T21:22:48Z","timestamp":1536700968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216300841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1096719216300841"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.009","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry in the older patient: Clinical consequences and possibilities for treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Shire Human Genetic Therapies. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}